AstraZeneca Pharma has secured approval from India's drug regulator for its cancer treatment Trastuzumab Deruxtecan. This drug is now approved for adult patients with unresectable or metastatic HER2-positive solid tumours. It is the first and only antibody drug conjugate in India with a tumour-agnostic indication. This broadens its potential to help more patients with advanced HER2-positive cancers.
from Industry-Economic Times https://ift.tt/wtnoFyL
via IFTTT
No comments:
Post a Comment
For Further Information, kindly click here!